Antithrombotic Therapy In Neonates And Children
Publication Date: February 1, 2012
Last Updated: March 14, 2022
Recommendations
Antithrombotic Therapy in Pediatric Patients
We suggest that where possible, pediatric hematologists with experience in TE manage pediatric patients with TE. (2, C)
307795
When this is not possible, we suggest a combination of a neonatologist/pediatrician and adult hematologist supported by consultation with an experienced pediatric hematologist. (2, C)
307795
Heparin in Neonates and Children
We suggest that therapeutic UFH in children is titrated to achieve a target range of anti-Xa activity of 0.35 to 0.7 units/mL or an aPTT range that correlates to this anti-Xa range or to a protamine titration range of 0.2 to 0.4 units/mL. (2, C)
307795
We suggest that when initiating UFH therapy, UFH boluses be no greater than 75 to 100 units/kg and that boluses be withheld or reduced if there are significant bleeding risks. (2, C)
307795
We suggest avoiding long-term use of therapeutic UFH in children. (2, C)
307795
Title
Antithrombotic Therapy In Neonates And Children
Authoring Organization
American College of Chest Physicians